Fusion Stock Analysis

FUSN -  USA Stock  

USD 8.28  0.15  1.78%

The big decline in price over the last few months for Fusion Pharmaceuticals could raise concerns from institutional investors as the firm it trading at a share price of 8.28 on 171,344 in volume. The company directors and management failed to add value to investors and positioning the firm supply of money to exploit market volatility in May. However, diversifying your holdings with Fusion Pharmaceuticals or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.1. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Fusion Pharmaceuticals partners.
Please check Investing Opportunities.

Search Stock Analysis 

 
Refresh
The Fusion Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Fusion Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Fusion stock analysis module also helps to analyze the Fusion Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Fusion Stock Analysis Notes

About 79.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada. Fusion Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 51 people. To learn more about Fusion Pharmaceuticals call the company at 289-799-0891 or check out http://fusionpharma.com.

Fusion Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Fusion Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Fusion Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Fusion Pharmaceuticals generates negative expected return over the last 90 days
Fusion Pharmaceuticals has high historical volatility and very poor performance
Fusion Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (79.72 M).
Fusion Pharmaceuticals currently holds about 222.4 M in cash with (29.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.32.
Over 79.0% of the company shares are owned by institutional investors
Latest headline from www.equities.com: Fusion Pharmaceuticals Inc falls -0.1210 percent for June 17 - Equities.com

Fusion Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Fusion Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Fusion Pharmaceuticals backward and forwards among themselves. Fusion Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Fusion Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Johnson Johnson InnovatioCommon Shares3.7 M39.3 M
Orbimed Advisors LlcCommon Shares3.2 M34.6 M
Fmr LlcCommon Shares3.1 M33.6 M
Canada Pension Plan Investment BoardCommon Shares3.1 M33.4 M
Adams Street Partners LlcCommon SharesM32 M
Tpg Group Holdings Sbs Advisors IncCommon Shares2.6 M27.4 M
Perceptive Advisors LlcCommon SharesM20.9 M
Note, although Fusion Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Fusion Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 346.35 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Fusion Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Fusion Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (12.48) % which means that it has lost $12.48 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (44.31) %, meaning that it created substantial loss on money invested by shareholders. Fusion Pharmaceuticals management efficiency ratios could be used to measure how well fusion pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 20th of June, Fusion Pharmaceuticals shows the coefficient of variation of (1,058), and Mean Deviation of 2.65. Fusion Pharmaceuticals technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to interpolate and collect nineteen technical drivers for Fusion Pharmaceuticals, which can be compared to its rivals. Please confirm Fusion Pharmaceuticals variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Fusion Pharmaceuticals is priced favorably, providing market reflects its regular price of 8.28 per share. Given that Fusion Pharmaceuticals has jensen alpha of (0.38), we urge you to verify Fusion Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.

Fusion Pharmaceuticals Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. View also all equity analysis or get more info about mavp overlap studies indicator.

Fusion Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fusion Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fusion Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Fusion Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Fusion Pharmaceuticals Technical and Predictive Indicators

Fusion Pharmaceuticals Forecast Models

Fusion Pharmaceuticals time-series forecasting models is one of many Fusion Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Fusion Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Fusion Pharmaceuticals Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Fusion Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Fusion shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Fusion Pharmaceuticals. By using and applying Fusion Stock analysis, traders can create a robust methodology for identifying Fusion entry and exit points for their positions.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada. Fusion Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 51 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Fusion Pharmaceuticals to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Commodity Channel Index Now

   

Commodity Channel Index

Use Commodity Channel Index to analyze current equity momentum
All  Next Launch Module
Please check Investing Opportunities. Note that the Fusion Pharmaceuticals information on this page should be used as a complementary analysis to other Fusion Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for Fusion Pharmaceuticals Stock analysis

When running Fusion Pharmaceuticals price analysis, check to measure Fusion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fusion Pharmaceuticals is operating at the current time. Most of Fusion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Fusion Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Fusion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Fusion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
The market value of Fusion Pharmaceuticals is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fusion Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Fusion Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.